Actos (pioglitazone) (DrugBank: Pioglitazone)
17 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 0 |
6 | パーキンソン病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 1 |
15 | 封入体筋炎 | 0 |
20 | 副腎白質ジストロフィー | 0 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 0 |
65 | 原発性免疫不全症候群 | 0 |
67 | 多発性嚢胞腎 | 0 |
78 | 下垂体前葉機能低下症 | 0 |
81 | 先天性副腎皮質酵素欠損症 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
96 | クローン病 | 0 |
229 | 肺胞蛋白症(自己免疫性又は先天性) | 0 |
265 | 脂肪萎縮症 | 0 |
298 | 遺伝性膵炎 | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00242177 (ClinicalTrials.gov) | October 2003 | 18/10/2005 | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Multiple Sclerosis, Relapsing-Remitting | Drug: ACTOS (Pioglitazone) | University of Illinois at Chicago | Takeda Pharmaceuticals North America, Inc. | Completed | 18 Years | 65 Years | All | 30 | Phase 1 | United States |